Phenotype and groups
Define the reliable functional phenotype, then group by response, model feature, dose or time.
Application
Disease mechanism & biomarkers
Interpret tissue-level, functional and molecular changes in the context of the model and treatment to identify reproducible, testable signals for R&D decisions.
Tissue and molecular evidence
Prioritize candidate markers from model identity and treatment response
HCC source-tissue/PDO histology with CD31 and HEP-1 establishes model and target context, while kidney organoid qPCR profiles KIM-1, H2AFX and inflammation/stress-related responses after cisplatin exposure. Studies can build from these measurable phenotypes into repeatable molecular assays and follow-on validation.
View imageTissue and model profiling: paired H&E, CD31 and HEP-1 immunohistochemistry in source tissue and PDO shows tissue architecture, vascular features and hepatic lineage markers, supporting model identity and the selection of target and mechanism readouts.
Model & assay data
View imageH9-derived | cisplatin molecular response: RT-qPCR profiles KIM-1, H2AFX and inflammation/stress-related genes across cisplatin conditions, helping prioritize kidney-injury biomarkers and define follow-on dose, timing and confirmatory assays.
TRiCBIO H9-derived kidney organoid cisplatin studyReview the full study
Continue to the related case for model context, experimental setup and interpretation.
Study focus
What this study can help you decide
- 01Which pathway changes track with a reliable phenotype?
- 02Which baseline features best distinguish response?
- 03Which candidate markers are reproducible across independent samples and orthogonal methods?
Study workflow
How the study moves from question to results
Mechanism-focused assays
Select histology, imaging, flow, qPCR, protein or secreted readouts around the hypothesis.
Data integration and candidate markers
Compare baseline, treatment response and mechanism readouts to identify reproducible candidate markers.
Independent validation and evidence building
Validate in additional samples or with orthogonal methods, strengthening the evidence from initial observation through independent confirmation.
Model options
Match the model to indication, mechanism and sample
Identify candidate signals associated with treatment response or mechanism, then build a validation plan using additional samples, prespecified analyses and orthogonal methods.
PROJECT DISCUSSION
Plan a mechanism or biomarker study
Disease context, existing phenotypes and data, comparison groups and the mechanism hypothesis shape the models, assays and complementary confirmation plan.